Approval of novel TB drug celebrated - with restraint

The U.S. Food and Drug Administration approved the drug, bedaquiline, for only patients who have multidrug-resistant tuberculosis, which can require up to 2 years of treatment. It is the first new tuberculosis drug to be green-lighted in more than 40 years, but the celebration was tempered as sobering challenges face the drug's wide scale use.